2021 / 06

Next Paper
DOI: 10.24075/brsmu.2021.065

ORIGINAL RESEARCH

Metabolic “footprints” of the circulating cancer mucins: CA125 in the high-grade ovarian cancer

Chagovets VV1, Vasil'ev VG2, Iurova MV1,3, Khabas GN1, Pavlovich SV1,3, Starodubtseva NL1, Mayboroda OA4,5
About authors

1 Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia

2 Peoples’ Friendship University of Russia, Moscow, Russia

3 Sechenov First Moscow State Medical University, Moscow, Russia

4 Leiden University Medical Center, Leiden, The Netherlands

5 Tomsk State University, Tomsk, Russia

Correspondence should be addressed: Vitaly V. Chagovets
Akademika Oparina, 4, Moscow, 117997, Russia; moc.liamg@stevogahcvv

About paper

Funding: the study was supported by a grant from the Russian Science Foundation (project #20-65-46014).

Author contribution: Chagovets VV — study planning, sample preparation, discussion of NMR data processing, manuscript authoring and editing; Vasil'ev VG — sample preparation, NMR analysis; Iurova MV, Khabas GN — collection and characterization of clinical samples, discussion of the results; Pavlovich SV — study research, discussion of the results; Starodubtseva NL — study planning, clinical data processing; Mayboroda OA — study planning and management, manuscript authoring, NMR data processing.

Compliance with ethical standards: the study was approved by the Ethics Committee of the V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology (Minutes #10 of December 05, 2019), conducted in accordance with federal laws of the Russian Federation (#152, 323 etc.) and the Declaration of Helsinki of 1964 with all subsequent extensions and amendments regulating scientific research involving biomaterials obtained from human beings.

Received: 2021-12-01 Accepted: 2021-12-16 Published online: 2021-12-29
|
  1. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004; 4 (1): 45–60. DOI: 10.1038/NRC1251.
  2. Yin BWT, Dnistrian A, Lloyd KO. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J cancer. 2002; 98 (5): 737–40. DOI: 10.1002/IJC.10250.
  3. Devine PL, McGuckin MA, Ward BG. Circulating mucins as tumor markers in ovarian cancer (review). Anticancer Res. 1992; 12 (3): 709–17. Accessed November 27, 2021. Available from: https:// www.researchgate.net/publication/21533861_Circulating_ mucins_as_tumor_markers_in_ovarian_cancer_Review.
  4. Pavlovich SV, Yurova MV, Melkumyan AG, Frankevich VE, Chagovets VV, Khabas GN. Biomarkers in ovarian neoplasms: opportunities, limitations, and prospects for using in reproductiveaged women. Akush Ginekol (Sofiia). 2019; 11 (2019): 65–73. DOI: 10.18565/aig.2019.11.65–73.
  5. Felder M, Kapur A, Gonzalez-Bosquet J, et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014; 13 (1): 1–15. DOI: 10.1186/1476-4598-13-129.
  6. Seyfried TN, Flores RE, Poff AM, D’Agostino DP. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis. 2014; 35 (3): 515. DOI:10.1093/CARCIN/BGT480.
  7. Coller HA. Is Cancer a Metabolic Disease? Am J Pathol. 2014; 184 (1): 4. DOI:10.1016/J.AJPATH.2013.07.035.
  8. Kaprin AD, Starinskij VV, Shahzadova AO, redaktory. Sostojanie onkologicheskoj pomoshhi naseleniju Rossii v 2019 godu. M.: MNIOI im. P. A. Gercena — filial FGBU «NMIC radiologii», 2020; 239 s.
  9. Psychogios N, Hau DD, Peng J, et al. The Human Serum Metabolome. PLoS One. 2011; 6 (2): e16957. DOI: 10.1371/ JOURNAL.PONE.0016957.
  10. Dorokhov YL, Shindyapina AV, Sheshukova EV, Komarova TV. Metabolic methanol: molecular pathways and physiological roles. Physiol Rev. 2015; 95 (2): 603–44. DOI: 10.1152/PHYSREV.00034.2014.
  11. Tang WHW, Wang Z, Kennedy DJ, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015; 116 (3): 448–55. DOI: 10.1161/CIRCRESAHA.116.305360.
  12. Lai HS, Lee JC, Lee PH, Wang ST, Chen WJ. Plasma free amino acid profile in cancer patients. Semin Cancer Biol. 2005; 15 (4): 267–76. DOI: 10.1016/J.SEMCANCER.2005.04.003.
  13. Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016; 16 (10): 619–34. DOI: 10.1038/NRC.2016.71.
  14. Youn J, Cho E, Lee JE. Association of choline and betaine levels with cancer incidence and survival: A meta-analysis. Clin Nutr. 2019; 38 (1): 100–09. DOI: 10.1016/J.CLNU.2018.01.042.